Basket | Login | Register


Athira Pharma presents results from Phase I/II trial of NDX-1017 in mild to moderate Alzheimer’s disease

Monday 09 December 2019

On 9 December, Athira Pharma, a drug development company aiming to improve human health by advancing new therapies for neurodegenerative diseases like Alzheimer’s disease (AD), presented initial data from its Phase Ia/II clinical trial of NDX-1017 at the 12th Clinical Trials in Alzheimer’s Disease (CTAD) conference.

The Phase Ia/II trial was designed as a randomised, placebo-controlled and double-blind study to evaluate the safety, tolerability and pharmacokinetics of NDX-1017 in healthy participants and participants with AD dementia. The company reported that the study enrolled 88 participants. In all treated cohorts, results showed dose-dependent and consistent changes in brain activity. NDX-1017 was reported to enhance key brain circuitry and normalise brain activity in people with mild-to-moderate AD.

“We are encouraged that we were able to show a robust and statistically significant improvement in an objective measure of a cognitive process in Alzheimer’s patients,” said Hans J. Moebius, MD, PhD, Chief Medical Officer, Athira Pharma.